Interferon Alfa-2a for chronic myeloid leukemia

J. Mehta; C. D. Atkins; B. J. Kennedy; S. Tura; M. Baccarani

doi:10.1056/NEJM199408113310614

Interferon Alfa-2a for chronic myeloid leukemia

J. Mehta, C. D. Atkins, B. J. Kennedy, S. Tura, M. Baccarani

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: The Italian Cooperative Study Group on Chronic Myeloid Leukemia demonstrated the substantial benefit of interferon in a compelling fashion (March 24 issue),¹ but the cost of therapy in the interferon group was 200 times higher than that in the chemotherapy group, and the quality of life for the patients receiving interferon was not very good because of the high incidence of systemic adverse effects. It would be interesting to compare the outcome in patients in the interferon group who had a hematologic response other than a complete or partial response after 8 months of therapy (Figure 3.

Original language	English (US)
Pages (from-to)	401-402
Number of pages	2
Journal	New England Journal of Medicine
Volume	331
Issue number	6
DOIs	https://doi.org/10.1056/NEJM199408113310614
State	Published - Aug 11 1994

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJM199408113310614

Cite this

@article{ee3aced5cc724458b62d401989a563dc,

title = "Interferon Alfa-2a for chronic myeloid leukemia",

abstract = "To the Editor: The Italian Cooperative Study Group on Chronic Myeloid Leukemia demonstrated the substantial benefit of interferon in a compelling fashion (March 24 issue),1 but the cost of therapy in the interferon group was 200 times higher than that in the chemotherapy group, and the quality of life for the patients receiving interferon was not very good because of the high incidence of systemic adverse effects. It would be interesting to compare the outcome in patients in the interferon group who had a hematologic response other than a complete or partial response after 8 months of therapy (Figure 3.",

author = "J. Mehta and Atkins, {C. D.} and Kennedy, {B. J.} and S. Tura and M. Baccarani",

year = "1994",

month = aug,

day = "11",

doi = "10.1056/NEJM199408113310614",

language = "English (US)",

volume = "331",

pages = "401--402",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "6",

}

TY - JOUR

T1 - Interferon Alfa-2a for chronic myeloid leukemia

AU - Mehta, J.

AU - Atkins, C. D.

AU - Kennedy, B. J.

AU - Tura, S.

AU - Baccarani, M.

PY - 1994/8/11

Y1 - 1994/8/11

N2 - To the Editor: The Italian Cooperative Study Group on Chronic Myeloid Leukemia demonstrated the substantial benefit of interferon in a compelling fashion (March 24 issue),1 but the cost of therapy in the interferon group was 200 times higher than that in the chemotherapy group, and the quality of life for the patients receiving interferon was not very good because of the high incidence of systemic adverse effects. It would be interesting to compare the outcome in patients in the interferon group who had a hematologic response other than a complete or partial response after 8 months of therapy (Figure 3.

AB - To the Editor: The Italian Cooperative Study Group on Chronic Myeloid Leukemia demonstrated the substantial benefit of interferon in a compelling fashion (March 24 issue),1 but the cost of therapy in the interferon group was 200 times higher than that in the chemotherapy group, and the quality of life for the patients receiving interferon was not very good because of the high incidence of systemic adverse effects. It would be interesting to compare the outcome in patients in the interferon group who had a hematologic response other than a complete or partial response after 8 months of therapy (Figure 3.

UR - http://www.scopus.com/inward/record.url?scp=0027990258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027990258&partnerID=8YFLogxK

U2 - 10.1056/NEJM199408113310614

DO - 10.1056/NEJM199408113310614

M3 - Letter

C2 - 8028627

AN - SCOPUS:0027990258

SN - 0028-4793

VL - 331

SP - 401

EP - 402

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 6

ER -

Interferon Alfa-2a for chronic myeloid leukemia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this